1. Home
  2. ICCC vs RFL Comparison

ICCC vs RFL Comparison

Compare ICCC & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • RFL
  • Stock Information
  • Founded
  • ICCC 1982
  • RFL 2017
  • Country
  • ICCC United States
  • RFL United States
  • Employees
  • ICCC N/A
  • RFL N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • RFL Real Estate
  • Sector
  • ICCC Health Care
  • RFL Finance
  • Exchange
  • ICCC Nasdaq
  • RFL Nasdaq
  • Market Cap
  • ICCC 60.1M
  • RFL 54.4M
  • IPO Year
  • ICCC 1987
  • RFL N/A
  • Fundamental
  • Price
  • ICCC $5.92
  • RFL $1.34
  • Analyst Decision
  • ICCC
  • RFL
  • Analyst Count
  • ICCC 0
  • RFL 0
  • Target Price
  • ICCC N/A
  • RFL N/A
  • AVG Volume (30 Days)
  • ICCC 7.7K
  • RFL 110.9K
  • Earning Date
  • ICCC 11-12-2025
  • RFL 11-05-2025
  • Dividend Yield
  • ICCC N/A
  • RFL N/A
  • EPS Growth
  • ICCC N/A
  • RFL N/A
  • EPS
  • ICCC 0.20
  • RFL N/A
  • Revenue
  • ICCC $28,274,756.00
  • RFL $732,000.00
  • Revenue This Year
  • ICCC N/A
  • RFL N/A
  • Revenue Next Year
  • ICCC N/A
  • RFL N/A
  • P/E Ratio
  • ICCC $30.55
  • RFL N/A
  • Revenue Growth
  • ICCC 21.75
  • RFL 35.56
  • 52 Week Low
  • ICCC $3.34
  • RFL $1.28
  • 52 Week High
  • ICCC $7.60
  • RFL $3.19
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 41.72
  • RFL 38.86
  • Support Level
  • ICCC $6.29
  • RFL $1.30
  • Resistance Level
  • ICCC $6.42
  • RFL $1.51
  • Average True Range (ATR)
  • ICCC 0.24
  • RFL 0.11
  • MACD
  • ICCC -0.02
  • RFL -0.00
  • Stochastic Oscillator
  • ICCC 1.82
  • RFL 12.90

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: